Delaware as well as the Northeast has one of the highest rates of Melanoma diagnoses in the US per year according to the CDC, and there is likewise no current cure for late stage melanoma. Thus the point of this project will be the expression of a melittin-azurin as well as a Colicin N-azurin chimeric proteins in order to test their efficacy against melanoma cancer cells in hopes of seeing tumor regression. Melittin is an antimicrobial peptide native to bees that has cytotoxic effects by means of cell membrane lysis by pore formation; Colicins are native to E. coli and have antimicrobial and anticancer properties similar to that of melittin; while azurin is a bacteriocin native to P. aeruginosa, and induces p53 mediated apoptosis. Both have cationic properties that allow for their selectivity of adhesion to cancerous cell lines. By combining these proteins using a GSG linker, we expect to see the synergistic effect of these proteins work in vivo and in vitro, better than their unconjoined counterparts. The directionality of the azurin and melittin inserts is likewise to be evaluated in order to gage whether the C or N terminus of either is directly involved in their cytotoxic activities.